nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—Lisinopril—ACE—psoriatic arthritis	0.025	1	CrCbGaD
Lisdexamfetamine—Euphoric mood—Prednisolone—psoriatic arthritis	0.00829	0.0085	CcSEcCtD
Lisdexamfetamine—Euphoric mood—Triamcinolone—psoriatic arthritis	0.00763	0.00782	CcSEcCtD
Lisdexamfetamine—Euphoric mood—Methylprednisolone—psoriatic arthritis	0.00761	0.0078	CcSEcCtD
Lisdexamfetamine—Visual disturbance—Prednisolone—psoriatic arthritis	0.00739	0.00758	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Auranofin—psoriatic arthritis	0.00739	0.00758	CcSEcCtD
Lisdexamfetamine—Euphoric mood—Dexamethasone—psoriatic arthritis	0.00692	0.0071	CcSEcCtD
Lisdexamfetamine—Euphoric mood—Betamethasone—psoriatic arthritis	0.00692	0.0071	CcSEcCtD
Lisdexamfetamine—Affect lability—Prednisolone—psoriatic arthritis	0.0069	0.00707	CcSEcCtD
Lisdexamfetamine—Vomiting—Auranofin—psoriatic arthritis	0.00687	0.00704	CcSEcCtD
Lisdexamfetamine—Rash—Auranofin—psoriatic arthritis	0.00681	0.00698	CcSEcCtD
Lisdexamfetamine—Dermatitis—Auranofin—psoriatic arthritis	0.0068	0.00698	CcSEcCtD
Lisdexamfetamine—Nausea—Auranofin—psoriatic arthritis	0.00641	0.00658	CcSEcCtD
Lisdexamfetamine—Affect lability—Triamcinolone—psoriatic arthritis	0.00634	0.0065	CcSEcCtD
Lisdexamfetamine—Affect lability—Methylprednisolone—psoriatic arthritis	0.00633	0.00649	CcSEcCtD
Lisdexamfetamine—Psychotic disorder—Methylprednisolone—psoriatic arthritis	0.00628	0.00644	CcSEcCtD
Lisdexamfetamine—Visual disturbance—Dexamethasone—psoriatic arthritis	0.00617	0.00633	CcSEcCtD
Lisdexamfetamine—Visual disturbance—Betamethasone—psoriatic arthritis	0.00617	0.00633	CcSEcCtD
Lisdexamfetamine—Irritability—Methylprednisolone—psoriatic arthritis	0.00614	0.00629	CcSEcCtD
Lisdexamfetamine—Euphoric mood—Prednisone—psoriatic arthritis	0.00603	0.00618	CcSEcCtD
Lisdexamfetamine—Affect lability—Dexamethasone—psoriatic arthritis	0.00575	0.0059	CcSEcCtD
Lisdexamfetamine—Affect lability—Betamethasone—psoriatic arthritis	0.00575	0.0059	CcSEcCtD
Lisdexamfetamine—Psychotic disorder—Betamethasone—psoriatic arthritis	0.00571	0.00585	CcSEcCtD
Lisdexamfetamine—Psychotic disorder—Dexamethasone—psoriatic arthritis	0.00571	0.00585	CcSEcCtD
Lisdexamfetamine—Irritability—Betamethasone—psoriatic arthritis	0.00558	0.00572	CcSEcCtD
Lisdexamfetamine—Irritability—Dexamethasone—psoriatic arthritis	0.00558	0.00572	CcSEcCtD
Lisdexamfetamine—Weight increased—Prednisolone—psoriatic arthritis	0.00551	0.00565	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Prednisolone—psoriatic arthritis	0.00532	0.00546	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Prednisolone—psoriatic arthritis	0.00529	0.00543	CcSEcCtD
Lisdexamfetamine—Weight increased—Triamcinolone—psoriatic arthritis	0.00507	0.0052	CcSEcCtD
Lisdexamfetamine—Weight increased—Methylprednisolone—psoriatic arthritis	0.00506	0.00519	CcSEcCtD
Lisdexamfetamine—Affect lability—Prednisone—psoriatic arthritis	0.00501	0.00514	CcSEcCtD
Lisdexamfetamine—Psychotic disorder—Prednisone—psoriatic arthritis	0.00497	0.0051	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Triamcinolone—psoriatic arthritis	0.00489	0.00502	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Methylprednisolone—psoriatic arthritis	0.00488	0.00501	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Triamcinolone—psoriatic arthritis	0.00487	0.00499	CcSEcCtD
Lisdexamfetamine—Irritability—Prednisone—psoriatic arthritis	0.00486	0.00498	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Methylprednisolone—psoriatic arthritis	0.00486	0.00498	CcSEcCtD
Lisdexamfetamine—Visual impairment—Prednisolone—psoriatic arthritis	0.00467	0.00479	CcSEcCtD
Lisdexamfetamine—Weight increased—Dexamethasone—psoriatic arthritis	0.0046	0.00472	CcSEcCtD
Lisdexamfetamine—Weight increased—Betamethasone—psoriatic arthritis	0.0046	0.00472	CcSEcCtD
Lisdexamfetamine—Weight decreased—Dexamethasone—psoriatic arthritis	0.00457	0.00469	CcSEcCtD
Lisdexamfetamine—Weight decreased—Betamethasone—psoriatic arthritis	0.00457	0.00469	CcSEcCtD
Lisdexamfetamine—Visual disturbance—Methotrexate—psoriatic arthritis	0.00449	0.0046	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Dexamethasone—psoriatic arthritis	0.00444	0.00455	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Betamethasone—psoriatic arthritis	0.00444	0.00455	CcSEcCtD
Lisdexamfetamine—Hallucination—Methylprednisolone—psoriatic arthritis	0.00442	0.00454	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Dexamethasone—psoriatic arthritis	0.00442	0.00453	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Betamethasone—psoriatic arthritis	0.00442	0.00453	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Methotrexate—psoriatic arthritis	0.00434	0.00445	CcSEcCtD
Lisdexamfetamine—Visual impairment—Methylprednisolone—psoriatic arthritis	0.00429	0.00439	CcSEcCtD
Lisdexamfetamine—Eye disorder—Methylprednisolone—psoriatic arthritis	0.00416	0.00426	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Methylprednisolone—psoriatic arthritis	0.00413	0.00423	CcSEcCtD
Lisdexamfetamine—Irritability—Methotrexate—psoriatic arthritis	0.00406	0.00416	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Prednisone—psoriatic arthritis	0.00405	0.00416	CcSEcCtD
Lisdexamfetamine—Hallucination—Betamethasone—psoriatic arthritis	0.00402	0.00413	CcSEcCtD
Lisdexamfetamine—Hallucination—Dexamethasone—psoriatic arthritis	0.00402	0.00413	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Methylprednisolone—psoriatic arthritis	0.00402	0.00412	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.00401	0.00411	CcSEcCtD
Lisdexamfetamine—Weight increased—Prednisone—psoriatic arthritis	0.004	0.00411	CcSEcCtD
Lisdexamfetamine—Weight decreased—Prednisone—psoriatic arthritis	0.00398	0.00408	CcSEcCtD
Lisdexamfetamine—Vision blurred—Prednisolone—psoriatic arthritis	0.00398	0.00408	CcSEcCtD
Lisdexamfetamine—Depression—Prednisone—psoriatic arthritis	0.00391	0.00401	CcSEcCtD
Lisdexamfetamine—Visual impairment—Dexamethasone—psoriatic arthritis	0.0039	0.004	CcSEcCtD
Lisdexamfetamine—Visual impairment—Betamethasone—psoriatic arthritis	0.0039	0.004	CcSEcCtD
Lisdexamfetamine—Mental disorder—Methylprednisolone—psoriatic arthritis	0.0039	0.004	CcSEcCtD
Lisdexamfetamine—Malnutrition—Methylprednisolone—psoriatic arthritis	0.00387	0.00397	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Prednisone—psoriatic arthritis	0.00387	0.00397	CcSEcCtD
Lisdexamfetamine—Angioedema—Prednisolone—psoriatic arthritis	0.00385	0.00395	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Prednisone—psoriatic arthritis	0.00385	0.00394	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Methotrexate—psoriatic arthritis	0.00383	0.00393	CcSEcCtD
Lisdexamfetamine—Eye disorder—Dexamethasone—psoriatic arthritis	0.00378	0.00388	CcSEcCtD
Lisdexamfetamine—Eye disorder—Betamethasone—psoriatic arthritis	0.00378	0.00388	CcSEcCtD
Lisdexamfetamine—Convulsion—Prednisolone—psoriatic arthritis	0.00366	0.00375	CcSEcCtD
Lisdexamfetamine—Hypertension—Prednisolone—psoriatic arthritis	0.00364	0.00374	CcSEcCtD
Lisdexamfetamine—Angioedema—Triamcinolone—psoriatic arthritis	0.00354	0.00364	CcSEcCtD
Lisdexamfetamine—Angioedema—Methylprednisolone—psoriatic arthritis	0.00354	0.00363	CcSEcCtD
Lisdexamfetamine—Hallucination—Prednisone—psoriatic arthritis	0.0035	0.00359	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.00344	0.00353	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Methotrexate—psoriatic arthritis	0.00339	0.00347	CcSEcCtD
Lisdexamfetamine—Convulsion—Triamcinolone—psoriatic arthritis	0.00336	0.00345	CcSEcCtD
Lisdexamfetamine—Tachycardia—Prednisolone—psoriatic arthritis	0.00336	0.00345	CcSEcCtD
Lisdexamfetamine—Convulsion—Methylprednisolone—psoriatic arthritis	0.00335	0.00344	CcSEcCtD
Lisdexamfetamine—Hypertension—Triamcinolone—psoriatic arthritis	0.00335	0.00344	CcSEcCtD
Lisdexamfetamine—Hypertension—Methylprednisolone—psoriatic arthritis	0.00334	0.00343	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.00333	0.00341	CcSEcCtD
Lisdexamfetamine—Eye disorder—Prednisone—psoriatic arthritis	0.00329	0.00338	CcSEcCtD
Lisdexamfetamine—Anxiety—Methylprednisolone—psoriatic arthritis	0.00328	0.00337	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.00327	0.00336	CcSEcCtD
Lisdexamfetamine—Depression—Methotrexate—psoriatic arthritis	0.00327	0.00335	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Methotrexate—psoriatic arthritis	0.00325	0.00333	CcSEcCtD
Lisdexamfetamine—Dry mouth—Triamcinolone—psoriatic arthritis	0.00323	0.00331	CcSEcCtD
Lisdexamfetamine—Angioedema—Dexamethasone—psoriatic arthritis	0.00322	0.0033	CcSEcCtD
Lisdexamfetamine—Angioedema—Betamethasone—psoriatic arthritis	0.00322	0.0033	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Prednisone—psoriatic arthritis	0.00318	0.00326	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.00317	0.00325	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.00316	0.00324	CcSEcCtD
Lisdexamfetamine—Insomnia—Prednisolone—psoriatic arthritis	0.00311	0.00319	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.0031	0.00318	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.0031	0.00318	CcSEcCtD
Lisdexamfetamine—Tachycardia—Triamcinolone—psoriatic arthritis	0.00309	0.00317	CcSEcCtD
Lisdexamfetamine—Mental disorder—Prednisone—psoriatic arthritis	0.00309	0.00316	CcSEcCtD
Lisdexamfetamine—Tachycardia—Methylprednisolone—psoriatic arthritis	0.00308	0.00316	CcSEcCtD
Lisdexamfetamine—Skin disorder—Methylprednisolone—psoriatic arthritis	0.00307	0.00315	CcSEcCtD
Lisdexamfetamine—Malnutrition—Prednisone—psoriatic arthritis	0.00307	0.00314	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.00306	0.00314	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.00305	0.00313	CcSEcCtD
Lisdexamfetamine—Convulsion—Betamethasone—psoriatic arthritis	0.00305	0.00313	CcSEcCtD
Lisdexamfetamine—Convulsion—Dexamethasone—psoriatic arthritis	0.00305	0.00313	CcSEcCtD
Lisdexamfetamine—Hypertension—Dexamethasone—psoriatic arthritis	0.00304	0.00312	CcSEcCtD
Lisdexamfetamine—Hypertension—Betamethasone—psoriatic arthritis	0.00304	0.00312	CcSEcCtD
Lisdexamfetamine—Anxiety—Dexamethasone—psoriatic arthritis	0.00299	0.00306	CcSEcCtD
Lisdexamfetamine—Anxiety—Betamethasone—psoriatic arthritis	0.00299	0.00306	CcSEcCtD
Lisdexamfetamine—Hepatitis—Methotrexate—psoriatic arthritis	0.00294	0.00302	CcSEcCtD
Lisdexamfetamine—Vision blurred—Prednisone—psoriatic arthritis	0.00289	0.00296	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.00287	0.00295	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.00287	0.00295	CcSEcCtD
Lisdexamfetamine—Insomnia—Triamcinolone—psoriatic arthritis	0.00286	0.00294	CcSEcCtD
Lisdexamfetamine—Insomnia—Methylprednisolone—psoriatic arthritis	0.00286	0.00293	CcSEcCtD
Lisdexamfetamine—Visual impairment—Methotrexate—psoriatic arthritis	0.00284	0.00291	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Triamcinolone—psoriatic arthritis	0.00282	0.0029	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.00282	0.00289	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Betamethasone—psoriatic arthritis	0.00282	0.00289	CcSEcCtD
Lisdexamfetamine—Agitation—Prednisone—psoriatic arthritis	0.00282	0.00289	CcSEcCtD
Lisdexamfetamine—Tachycardia—Dexamethasone—psoriatic arthritis	0.0028	0.00288	CcSEcCtD
Lisdexamfetamine—Tachycardia—Betamethasone—psoriatic arthritis	0.0028	0.00288	CcSEcCtD
Lisdexamfetamine—Angioedema—Prednisone—psoriatic arthritis	0.0028	0.00287	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Triamcinolone—psoriatic arthritis	0.00279	0.00286	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Methotrexate—psoriatic arthritis	0.00278	0.00285	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.00278	0.00285	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.00278	0.00285	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.00278	0.00285	CcSEcCtD
Lisdexamfetamine—Eye disorder—Methotrexate—psoriatic arthritis	0.00275	0.00282	CcSEcCtD
Lisdexamfetamine—Anorexia—Dexamethasone—psoriatic arthritis	0.00274	0.00281	CcSEcCtD
Lisdexamfetamine—Anorexia—Betamethasone—psoriatic arthritis	0.00274	0.00281	CcSEcCtD
Lisdexamfetamine—Urticaria—Prednisolone—psoriatic arthritis	0.00274	0.00281	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Methotrexate—psoriatic arthritis	0.00273	0.0028	CcSEcCtD
Lisdexamfetamine—Fatigue—Triamcinolone—psoriatic arthritis	0.00273	0.0028	CcSEcCtD
Lisdexamfetamine—Fatigue—Methylprednisolone—psoriatic arthritis	0.00272	0.00279	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Methotrexate—psoriatic arthritis	0.00266	0.00273	CcSEcCtD
Lisdexamfetamine—Convulsion—Prednisone—psoriatic arthritis	0.00266	0.00272	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.00265	0.00272	CcSEcCtD
Lisdexamfetamine—Hypertension—Prednisone—psoriatic arthritis	0.00265	0.00271	CcSEcCtD
Lisdexamfetamine—Anxiety—Prednisone—psoriatic arthritis	0.0026	0.00267	CcSEcCtD
Lisdexamfetamine—Insomnia—Dexamethasone—psoriatic arthritis	0.0026	0.00266	CcSEcCtD
Lisdexamfetamine—Insomnia—Betamethasone—psoriatic arthritis	0.0026	0.00266	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.00259	0.00266	CcSEcCtD
Lisdexamfetamine—Mental disorder—Methotrexate—psoriatic arthritis	0.00258	0.00264	CcSEcCtD
Lisdexamfetamine—Malnutrition—Methotrexate—psoriatic arthritis	0.00256	0.00263	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Prednisolone—psoriatic arthritis	0.00254	0.0026	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Dexamethasone—psoriatic arthritis	0.00253	0.00259	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Betamethasone—psoriatic arthritis	0.00253	0.00259	CcSEcCtD
Lisdexamfetamine—Urticaria—Triamcinolone—psoriatic arthritis	0.00252	0.00258	CcSEcCtD
Lisdexamfetamine—Urticaria—Methylprednisolone—psoriatic arthritis	0.00251	0.00257	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Triamcinolone—psoriatic arthritis	0.0025	0.00257	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Prednisone—psoriatic arthritis	0.0025	0.00257	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Betamethasone—psoriatic arthritis	0.0025	0.00256	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Dexamethasone—psoriatic arthritis	0.0025	0.00256	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.00248	0.00254	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.00248	0.00254	CcSEcCtD
Lisdexamfetamine—Fatigue—Dexamethasone—psoriatic arthritis	0.00248	0.00254	CcSEcCtD
Lisdexamfetamine—Fatigue—Betamethasone—psoriatic arthritis	0.00248	0.00254	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Prednisone—psoriatic arthritis	0.00245	0.00252	CcSEcCtD
Lisdexamfetamine—Tachycardia—Prednisone—psoriatic arthritis	0.00244	0.0025	CcSEcCtD
Lisdexamfetamine—Skin disorder—Prednisone—psoriatic arthritis	0.00243	0.00249	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Prednisone—psoriatic arthritis	0.00242	0.00248	CcSEcCtD
Lisdexamfetamine—Vision blurred—Methotrexate—psoriatic arthritis	0.00241	0.00248	CcSEcCtD
Lisdexamfetamine—Anorexia—Prednisone—psoriatic arthritis	0.00238	0.00245	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.00233	0.00239	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.00233	0.00239	CcSEcCtD
Lisdexamfetamine—Urticaria—Dexamethasone—psoriatic arthritis	0.00228	0.00234	CcSEcCtD
Lisdexamfetamine—Urticaria—Betamethasone—psoriatic arthritis	0.00228	0.00234	CcSEcCtD
Lisdexamfetamine—Dizziness—Prednisolone—psoriatic arthritis	0.00228	0.00234	CcSEcCtD
Lisdexamfetamine—Asthenia—Triamcinolone—psoriatic arthritis	0.00227	0.00233	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Betamethasone—psoriatic arthritis	0.00227	0.00233	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Dexamethasone—psoriatic arthritis	0.00227	0.00233	CcSEcCtD
Lisdexamfetamine—Asthenia—Methylprednisolone—psoriatic arthritis	0.00227	0.00232	CcSEcCtD
Lisdexamfetamine—Insomnia—Prednisone—psoriatic arthritis	0.00226	0.00232	CcSEcCtD
Lisdexamfetamine—Convulsion—Methotrexate—psoriatic arthritis	0.00222	0.00228	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Prednisone—psoriatic arthritis	0.0022	0.00226	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Prednisone—psoriatic arthritis	0.00217	0.00223	CcSEcCtD
Lisdexamfetamine—Rash—Prednisolone—psoriatic arthritis	0.00217	0.00223	CcSEcCtD
Lisdexamfetamine—Dermatitis—Prednisolone—psoriatic arthritis	0.00217	0.00222	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.00217	0.00222	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.00216	0.00222	CcSEcCtD
Lisdexamfetamine—Fatigue—Prednisone—psoriatic arthritis	0.00216	0.00221	CcSEcCtD
Lisdexamfetamine—Headache—Prednisolone—psoriatic arthritis	0.00216	0.00221	CcSEcCtD
Lisdexamfetamine—Constipation—Prednisone—psoriatic arthritis	0.00214	0.00219	CcSEcCtD
Lisdexamfetamine—Dizziness—Triamcinolone—psoriatic arthritis	0.00209	0.00215	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.00209	0.00214	CcSEcCtD
Lisdexamfetamine—Dizziness—Methylprednisolone—psoriatic arthritis	0.00209	0.00214	CcSEcCtD
Lisdexamfetamine—Asthenia—Dexamethasone—psoriatic arthritis	0.00206	0.00211	CcSEcCtD
Lisdexamfetamine—Asthenia—Betamethasone—psoriatic arthritis	0.00206	0.00211	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Methotrexate—psoriatic arthritis	0.00205	0.0021	CcSEcCtD
Lisdexamfetamine—Nausea—Prednisolone—psoriatic arthritis	0.00205	0.0021	CcSEcCtD
Lisdexamfetamine—Skin disorder—Methotrexate—psoriatic arthritis	0.00203	0.00208	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.00202	0.00207	CcSEcCtD
Lisdexamfetamine—Vomiting—Triamcinolone—psoriatic arthritis	0.00201	0.00206	CcSEcCtD
Lisdexamfetamine—Vomiting—Methylprednisolone—psoriatic arthritis	0.00201	0.00206	CcSEcCtD
Lisdexamfetamine—Rash—Triamcinolone—psoriatic arthritis	0.002	0.00205	CcSEcCtD
Lisdexamfetamine—Dermatitis—Triamcinolone—psoriatic arthritis	0.00199	0.00205	CcSEcCtD
Lisdexamfetamine—Anorexia—Methotrexate—psoriatic arthritis	0.00199	0.00204	CcSEcCtD
Lisdexamfetamine—Rash—Methylprednisolone—psoriatic arthritis	0.00199	0.00204	CcSEcCtD
Lisdexamfetamine—Dermatitis—Methylprednisolone—psoriatic arthritis	0.00199	0.00204	CcSEcCtD
Lisdexamfetamine—Urticaria—Prednisone—psoriatic arthritis	0.00199	0.00204	CcSEcCtD
Lisdexamfetamine—Headache—Triamcinolone—psoriatic arthritis	0.00198	0.00203	CcSEcCtD
Lisdexamfetamine—Headache—Methylprednisolone—psoriatic arthritis	0.00198	0.00203	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Prednisone—psoriatic arthritis	0.00198	0.00203	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Dexamethasone—psoriatic arthritis	0.00197	0.00202	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Betamethasone—psoriatic arthritis	0.00197	0.00202	CcSEcCtD
Lisdexamfetamine—Dizziness—Betamethasone—psoriatic arthritis	0.0019	0.00195	CcSEcCtD
Lisdexamfetamine—Dizziness—Dexamethasone—psoriatic arthritis	0.0019	0.00195	CcSEcCtD
Lisdexamfetamine—Insomnia—Methotrexate—psoriatic arthritis	0.00189	0.00194	CcSEcCtD
Lisdexamfetamine—Nausea—Triamcinolone—psoriatic arthritis	0.00188	0.00193	CcSEcCtD
Lisdexamfetamine—Nausea—Methylprednisolone—psoriatic arthritis	0.00188	0.00192	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Methotrexate—psoriatic arthritis	0.00186	0.00191	CcSEcCtD
Lisdexamfetamine—Somnolence—Methotrexate—psoriatic arthritis	0.00186	0.00191	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Prednisone—psoriatic arthritis	0.00184	0.00189	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Methotrexate—psoriatic arthritis	0.00184	0.00189	CcSEcCtD
Lisdexamfetamine—Vomiting—Betamethasone—psoriatic arthritis	0.00183	0.00187	CcSEcCtD
Lisdexamfetamine—Vomiting—Dexamethasone—psoriatic arthritis	0.00183	0.00187	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Methotrexate—psoriatic arthritis	0.00182	0.00186	CcSEcCtD
Lisdexamfetamine—Rash—Betamethasone—psoriatic arthritis	0.00181	0.00186	CcSEcCtD
Lisdexamfetamine—Rash—Dexamethasone—psoriatic arthritis	0.00181	0.00186	CcSEcCtD
Lisdexamfetamine—Dermatitis—Dexamethasone—psoriatic arthritis	0.00181	0.00186	CcSEcCtD
Lisdexamfetamine—Dermatitis—Betamethasone—psoriatic arthritis	0.00181	0.00186	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.00181	0.00185	CcSEcCtD
Lisdexamfetamine—Fatigue—Methotrexate—psoriatic arthritis	0.0018	0.00185	CcSEcCtD
Lisdexamfetamine—Headache—Betamethasone—psoriatic arthritis	0.0018	0.00185	CcSEcCtD
Lisdexamfetamine—Headache—Dexamethasone—psoriatic arthritis	0.0018	0.00185	CcSEcCtD
Lisdexamfetamine—Asthenia—Prednisone—psoriatic arthritis	0.0018	0.00184	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Prednisone—psoriatic arthritis	0.00171	0.00176	CcSEcCtD
Lisdexamfetamine—Nausea—Dexamethasone—psoriatic arthritis	0.00171	0.00175	CcSEcCtD
Lisdexamfetamine—Nausea—Betamethasone—psoriatic arthritis	0.00171	0.00175	CcSEcCtD
Lisdexamfetamine—Urticaria—Methotrexate—psoriatic arthritis	0.00166	0.0017	CcSEcCtD
Lisdexamfetamine—Dizziness—Prednisone—psoriatic arthritis	0.00165	0.0017	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Methotrexate—psoriatic arthritis	0.00165	0.0017	CcSEcCtD
Lisdexamfetamine—Vomiting—Prednisone—psoriatic arthritis	0.00159	0.00163	CcSEcCtD
Lisdexamfetamine—Rash—Prednisone—psoriatic arthritis	0.00158	0.00162	CcSEcCtD
Lisdexamfetamine—Dermatitis—Prednisone—psoriatic arthritis	0.00158	0.00162	CcSEcCtD
Lisdexamfetamine—Headache—Prednisone—psoriatic arthritis	0.00157	0.00161	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Methotrexate—psoriatic arthritis	0.00154	0.00158	CcSEcCtD
Lisdexamfetamine—Asthenia—Methotrexate—psoriatic arthritis	0.0015	0.00154	CcSEcCtD
Lisdexamfetamine—Nausea—Prednisone—psoriatic arthritis	0.00149	0.00152	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Methotrexate—psoriatic arthritis	0.00143	0.00147	CcSEcCtD
Lisdexamfetamine—Dizziness—Methotrexate—psoriatic arthritis	0.00138	0.00142	CcSEcCtD
Lisdexamfetamine—Vomiting—Methotrexate—psoriatic arthritis	0.00133	0.00136	CcSEcCtD
Lisdexamfetamine—Rash—Methotrexate—psoriatic arthritis	0.00132	0.00135	CcSEcCtD
Lisdexamfetamine—Dermatitis—Methotrexate—psoriatic arthritis	0.00132	0.00135	CcSEcCtD
Lisdexamfetamine—Headache—Methotrexate—psoriatic arthritis	0.00131	0.00134	CcSEcCtD
Lisdexamfetamine—Nausea—Methotrexate—psoriatic arthritis	0.00124	0.00127	CcSEcCtD
